Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23426186 | 1.00 | SLC6A2 (0.38) | SLC6A2HTR2CCFTRBACE1APLNR | |
| SCHEMBL21767420 | 0.79 | CFTR (0.42) | SLC6A2HTR2CCFTRAPLNRHTR2A | |
| SCHEMBL21780595 | 0.79 | CFTR (0.42) | SLC6A2HTR2CCFTRAPLNRHTR2A | |
| SCHEMBL31072015 | 0.79 | CFTR (0.42) | SLC6A2HTR2CCFTRAPLNRHTR2A | |
| SCHEMBL29429452 | 0.79 | CFTR (0.42) | SLC6A2HTR2CCFTRAPLNRHTR2A | |
| SCHEMBL31071934 | 0.79 | CFTR (0.42) | SLC6A2HTR2CCFTRAPLNRHTR2A | |
| SCHEMBL21767551 | 0.79 | CFTR (0.42) | SLC6A2HTR2CCFTRAPLNRHTR2A | |
| SCHEMBL23647736 | 0.75 | CYP1A2 (0.39) | SLC6A2CFTRAPLNR | |
| SCHEMBL21767595 | 0.75 | PTGDR2 (0.40) | CFTR | |
| SCHEMBL21767407 | 0.75 | PTGDR2 (0.40) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | SLC6A2 3316/4885HTR2C 4761/4885CFTR 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.